SCHEMBL30977769

SCHEMBL30977769

CCCCCCC(CSCCCCCC(CCCCCOC(=O)C1CCCCCCCCCCCCCC1)NCCCCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)OC(=O)CCC1CCCCC1

nearest known ligand 0.33

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KLK7 P49862 4/20 0.33
▸ BCHE P06276 6/20 0.33
▸ ACHE P22303 5/20 0.33
▸ TLR2 O60603 5/20 0.32
▸ TDP1 Q9NUW8 1/20 0.31
▸ CACNA1F O60840 1/20 0.31
▸ CACNA1D Q01668 1/20 0.31
▸ CACNA1S Q13698 1/20 0.31
▸ CACNA1C Q13936 1/20 0.31
▸ CHRM2 P08172 1/20 0.30
▸ CHRM4 P08173 1/20 0.30
▸ CHRM5 P08912 1/20 0.30
▸ CHRM1 P11229 1/20 0.30
▸ CHRM3 P20309 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30977707 0.95 KLK7 (0.37) KLK7BCHEACHETLR2TDP1
SCHEMBL30977717 0.95 KLK7 (0.37) KLK7BCHEACHETLR2TDP1
SCHEMBL30977701 0.94 KLK7 (0.34) KLK7BCHEACHETLR2TDP1
SCHEMBL30977742 0.94 KLK7 (0.36) KLK7BCHETLR2TDP1
SCHEMBL30977766 0.90 CTSK (0.33) BCHEACHE
SCHEMBL30977728 0.89 BCHE (0.32) BCHEACHECACNA1FCACNA1DCACNA1S
SCHEMBL30977750 0.89 KLK7 (0.34) KLK7BCHEACHETDP1CACNA1F
SCHEMBL30977730 0.88 KLK7 (0.32) KLK7BCHEACHETLR2CHRM2
SCHEMBL30977698 0.88 BCHE (0.33) BCHEACHETLR2TDP1
SCHEMBL30977723 0.86 TLR2 (0.39) TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638417-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS Nanovation Therapeutics Inc. (CA) 2025-10-29 — — EP disclosed
WO-2025035202-A1 IONIZABLE LIPIDS COMPRISING MACROCYCLIC RINGS FOR THE DELIVERY OF THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2025-02-20 — — WO disclosed
US-20240398977-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-12-05 — — US disclosed
US-12121591-B2 Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents NANOVATION THERAPEUTICS INC. (CA) 2024-10-22 — — US disclosed
US-20240261430-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-08-08 — — US disclosed
WO-2024130421-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12121591-B2 Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents SLC43A1, NSUN3, NSUN2 KLK7 3697/4885BCHE 3833/4885ACHE 4820/4885
US-20240261430-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS SLC43A1, NSUN3, NSUN2 KLK7 3697/4885BCHE 3833/4885ACHE 4820/4885
US-20240398977-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS SLC43A1, NSUN3, NSUN2 KLK7 3697/4885BCHE 3833/4885ACHE 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback